JDRF wants Denver residents to be ‘T1D Aware’
DENVER The Juvenile Diabetes Research Foundation launched an awareness campaign in the Denver area to shed light on key signs of Type 1 diabetes.
The T1D Aware campaign addresses such signs of Type 1 diabetes as frequent urination and excessive thirst, and encourages parents to seek medical attention if they notice these signs in their children. JDRF said that in Colorado, approximately 40% of children who are newly diagnosed with Type 1 diabetes present with a life-threatening condition called diabetic ketoacidosis, which occurs when the body breaks down fat for energy instead of sugar.
As part of the campaign, JDRF will be distributing information and conducting local events across Denver. JDRF also has promoted its campaign in Houston and San Francisco.
FDA approves emergency contraceptive Ella
SILVER SPRING, Md. The Food and Drug Administration has approved an emergency contraceptive pill made by a French drug maker.
The FDA announced the approval of Ella (ulipristal acetate), designed to prevent pregnancy when taken orally within five days of unprotected sex or contraceptive failure, though it is not designed for routine use as a contraceptive.
The drug, which works by preventing ovulation, is manufactured by Paris-based Laboratoire HRA Pharma and distributed by Morristown, N.J.-based Watson. Watson said it plans to launch the drug in the fourth quarter of this year.
Meda ventures into generic drugs
SOMERSET, N.J. A lot of generic drug companies have conducted business in the branded drug market on the side for a long time, with Teva Pharmaceutical Industries and Watson Pharmaceuticals standing out as good examples. But lately, some branded drug companies have sought to get into generics as well.
Meda Pharmaceuticals, the U.S. subsidiary of Swedish drug maker Meda A.B., recently decided to create its own generics subsidiary, calling it Wallace Pharmaceuticals, senior marketing director John White told Drug Store News.
“The strategy demonstrates Meda’s efforts to diversify and align and better serve the needs [and] interest of our customers,” White said. “We believe our ability to provide consistency in therapeutic effect, manufacturing and supply to our parent company’s branded products will prove to be a competitive advantage for Wallace Pharmaceuticals.”
Wallace will focus its business in the United States, with a core portfolio of allergy and pain medicines, White said. The company currently has no plans to enter the biosimilars market, however.